Phosphodiesterase type 5 (PDE5) inhibitors are the most commonly used treatment for erectile dysfunction (ED).
Since the launch of sildenafil, several drugs-including mirodenafil, sildenafil citrate (sildenafil), tadalafil, vardenafil HCL (vardenafil), udenafil, and avanafil-have become available. Mirodenafil is a newly developed pyrrolopyrimidinone compound, which is a potent, reversible, and selective oral PDE5 inhibitor. Mirodenafil was launched in Korea in 2007, and an orally disintegrating film of mirodenafil was developed in 2011 for benefitting patients having difficulty in swallowing tablets. This study aimed to review the pharmacokinetic characteristic profile of mirodenafil and report evidence on its efficacy in the case of ED. In addition, we reviewed randomized controlled studies of mirodenafil's daily administration and efficacy for lower urinary tract symptoms.
Written by:
Park HJ, Moon KH, Lee SW, Lee WK, Kam SC, Lee JH, Park NC. Are you the author?
Department of Urology, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea; Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea; Department of Urology, Hanyang University Guri Hospital, Guri, Korea; Department of Urology, Chuncheon Sacred Heart Hospital, Hallym Unversity College of Medicine, Chuncheon, Korea; Department of Urology, Gyeongsang National University School of Medicine, Jinju, Korea; Department of Urology, National Police Hospital, Seoul, Korea.
Reference: World J Mens Health. 2014 Apr;32(1):18-27.
doi: 10.5534/wjmh.2014.32.1.18
PubMed Abstract
PMID: 24872948
UroToday.com Erectile Dysfunction Section
